Non-invasive processing of ultrasound images to detect, measure, and calculate relevant medical parameters of structures and function in patients with suspected disease, with Quality Score feedback.
Clinical role
Offline post-acquisition DICOM-clip analysis with automated frame selection, measurements, quality feedback, manual adjustment or editing, and visual confirmation as part of standard echocardiographic assessment.
Images and patients
Ultrasound · Heart and cardiovascular structures, especially the left and right ventricles; a bladder-volume module is also described
Key limitation
The FDA indication is broad, while the reported validation cohort included adults aged 18 years or older in sinus rhythm without multiple premature beats and excluded patients with LBBB. The packet reports 99 of 121 exams automatically analyzed and 90% of 40 additional PLAX exams automatically analyzed; results require clinical review and the study criteria do not establish performance for all patient or rhythm groups.
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Imaging and anatomyUltrasound · Heart and cardiovascular structures, especially the left and right ventricles; a bladder-volume module is also described
Workflow roleOffline post-acquisition DICOM-clip analysis with automated frame selection, measurements, quality feedback, manual adjustment or editing, and visual confirmation as part of standard echocardiographic assessment.
Required inputDICOM echocardiographic movies or clips from any vendor, including apical 2CH, 3CH, and 4CH views and parasternal short-axis and long-axis views; the platform also processes clips for RV and bladder evaluation.
Output and human actionQuality Score feedback plus EF, strain, segmental wall motion, RV, SAX, PLAX, and bladder results; automated LV size and function parameters and measurements with user visualization and editing or confirmation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Non-invasive processing of ultrasound images to detect, measure, and calculate relevant medical parameters of structures and function in patients with suspected disease, with Quality Score feedback.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Offline post-acquisition DICOM-clip analysis with automated frame selection, measurements, quality feedback, manual adjustment or editing, and visual confirmation as part of standard echocardiographic assessment.
DICOM echocardiographic movies or clips from any vendor, including apical 2CH, 3CH, and 4CH views and parasternal short-axis and long-axis views; the platform also processes clips for RV and bladder evaluation.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Quality Score feedback plus EF, strain, segmental wall motion, RV, SAX, PLAX, and bladder results; automated LV size and function parameters and measurements with user visualization and editing or confirmation.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
The FDA indication is broad, while the reported validation cohort included adults aged 18 years or older in sinus rhythm without multiple premature beats and excluded patients with LBBB. The packet reports 99 of 121 exams automatically analyzed and 90% of 40 additional PLAX exams automatically analyzed; results require clinical review and the study criteria do not establish performance for all patient or rhythm groups.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
FDA clinical validation used 121 routine transthoracic echocardiography patients; 99 exams (82%) were automatically analyzed. The primary endpoint was correlation of Fractional Shortening against the average manual measurements of two sonographers, r=0.79, with an acceptance criterion of at least 0.75. Sensitivity and specificity were each 85% at a 28% cutoff. An additional 40-patient U.S. dataset had 90% automatic analysis; the retrieved exact text states that PLAX results are provided below but does not expose the numeric table values.
Exact FDA submission
Checked 2026-09-19
The retrieved exact text supports the 121-patient and 40-patient study facts but does not expose the numeric PLAX correlation range in the active dossier.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA clinical validation used 121 routine transthoracic echocardiography patients; 99 exams (82%) were automatically analyzed. The primary endpoint was correlation of Fractional Shortening against the average manual measurements of two sonographers, r=0.79, with an acceptance criterion of at least 0.75. Sensitivity and specificity were each 85% at a 28% cutoff. An additional 40-patient U.S. dataset had 90% automatic analysis; the retrieved exact text states that PLAX results are provided below but does not expose the numeric table values.
FDA source
Exact FDA submission
Checked 2026-09-19
The retrieved exact text supports the 121-patient and 40-patient study facts but does not expose the numeric PLAX correlation range in the active dossier.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
LVivo Software Application regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K240553
Samplen=121
IndependenceIndependence not established
K240553
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240553. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM echocardiographic movies or clips from any vendor, including apical 2CH, 3CH, and 4CH views and parasternal short-axis and long-axis views; the platform also processes clips for RV and bladder evaluation.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Processes off-line DICOM clips from any vendor on Windows or Linux, with an Android option for LVivo EF noted in the comparison table. The FDA packet does not establish a specific PACS, RIS, EHR, cloud, or local interface contract.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: Quality Score feedback plus EF, strain, segmental wall motion, RV, SAX, PLAX, and bladder results; automated LV size and function parameters and measurements with user visualization and editing or confirmation.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Quality Score feedback plus EF, strain, segmental wall motion, RV, SAX, PLAX, and bladder results; automated LV size and function parameters and measurements with user visualization and editing or confirmation.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Processes off-line DICOM clips from any vendor on Windows or Linux, with an Android option for LVivo EF noted in the comparison table. The FDA packet does not establish a specific PACS, RIS, EHR, cloud, or local interface contract.
ACR AI Central provides an exact-submission model card for LVivo Software Application; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
23Fields reviewed
10Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Intended users: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not name the intended users of the subject device. Confirm intended operators and readers with the vendor.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K240553 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
Non-invasive processing of ultrasound images to detect, measure, and calculate medical parameters of structures and function in patients with suspected disease, with Quality Score feedback; the submitted IQS module provides real-time quality scoring for the left ventricle from the four-chamber apical view.
Modality
Ultrasound
Anatomy
Heart; left ventricle from the four-chamber apical view
Non-invasive processing of previously acquired echocardiographic images to detect and measure the left-ventricular wall and calculate left-ventricular function.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.